Contracts › 75A50124C00062
75A50124C00062: Development of Hopo-101 As an Mcm (Medical Countermeasure) Decorporation Agent for the Treatment of Individuals With Known or Suspected Internal Contamination With Radionuclides (The ?Mcm Indication?) And/Or Toxic Heavy Metals of Interest for Commerc
Awarded to Hopo Therapeutics, Inc. by Office of Assistant Secretary for Preparedness and Response.
$14.2Mobligated
$231.1Mpotential value
31 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50124C00062 |
|---|---|
| Awardee | Hopo Therapeutics, Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | Q701 Specialized Medical Support |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 30 September 2024 to 31 December 2026 |
| Potential end | 30 September 2029 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record